Stock News

Pinnacle Holdings Raised By $11.73 Million Its Hawthorn Bancshares (HWBK) Position; Seattle Genetics (SGEN) Has 1.3 Sentiment

Pinnacle Holdings Llc increased Hawthorn Bancshares (HWBK) stake by 3% reported in 2017Q2 SEC filing. Pinnacle Holdings Llc acquired 560 shares as Hawthorn Bancshares (HWBK)’s stock rose 3.46%. The Pinnacle Holdings Llc holds 19,199 shares with $402.22 million value, up from 18,639 last quarter. Hawthorn Bancshares now has $117.32 million valuation. The stock increased 0.37% or $0.0745 during the last trading session, reaching $20.2245. About 100 shares traded. Hawthorn Bancshares, Inc. (NASDAQ:HWBK) has risen 46.25% since December 7, 2016 and is uptrending. It has outperformed by 29.55% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $8.19 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on February, 8. They expect $-0.44 earnings per share, down 12.82% or $0.05 from last year’s $-0.39 per share. After $-0.19 actual earnings per share reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 131.58% negative EPS growth.

Baker Bros. Advisors Lp holds 20.68% of its portfolio in Seattle Genetics, Inc. for 45.73 million shares. Lagoda Investment Management L.P. owns 398,529 shares or 7.88% of their US portfolio. Moreover, Ghost Tree Capital Llc has 3.23% invested in the company for 300,000 shares. The California-based Redmile Group Llc has invested 2.09% in the stock. Eventide Asset Management Llc, a Massachusetts-based fund reported 525,000 shares.

The stock increased 0.32% or $0.18 during the last trading session, reaching $56.93. About 80,226 shares traded. Seattle Genetics, Inc. (SGEN) has risen 75.68% since December 7, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Ratings analysis reveals 40% of Seattle Genetics’s analysts are positive. Out of 5 Wall Street analysts rating Seattle Genetics, 2 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. SGEN was included in 5 notes of analysts from September 7, 2016. The stock has “Outperform” rating by RBC Capital Markets on Monday, October 10. Goldman Sachs upgraded the shares of SGEN in report on Thursday, September 15 to “Neutral” rating. The firm earned “Overweight” rating on Wednesday, September 7 by Morgan Stanley. The firm earned “Underperform” rating on Friday, February 10 by Bank of America. The rating was downgraded by Credit Suisse to “Neutral” on Monday, December 12.

Pinnacle Holdings Llc decreased Titan Machinery (Prn) stake by 20,000 shares to 2.51M valued at $2.42B in 2017Q2. It also reduced Iridium Communications stake by 135 shares and now owns 19,336 shares. Kimball Electronics (NASDAQ:KE) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *